Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma

1. Morishita A and Masaki T: miRNA in hepatocellular carcinoma.

Hepatol Res 45: 128‑141, 2015.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‑Tieulent J and

Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65:

87‑108, 2015.

3. Lacaze L and Scotté M: Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol 7: 1755‑1760,

2015.

4. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K,

Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S

and Makuuchi M: Risk factors contributing to early and late

phase intrahepatic recurrence of hepatocellular carcinoma after

hepatectomy. J Hepatol 38: 200‑207, 2003.

5. Venook AP, Papandreou C, Furuse J and de Guevara LL: The

incidence and epidemiology of hepatocellular carcinoma: A global

and regional perspective. Oncologist 15 (Suppl 4): S5‑S13, 2010.

6. Kudo M: Systemic therapy for hepatocellular carcinoma: 2017

update. Oncology 93 (Suppl 1): S135‑S146, 2017.

7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,

de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib

in advanced hepatocellular carcinoma. N Engl J Med 359:

378‑390, 2008.

8. Pelosof L, Lemery S, Casak S, Jiang X, Rodriguez L, Pierre V,

Bi Y, Liu J, Zirkelbach JF, Patel A, et al: Benefit‑risk summary

of regorafenib for the treatment of patients with advanced

hepatocellular carcinoma that has progressed on Sorafenib.

Oncologist 23: 496‑500, 2018.

9. Belghiti J and Kianmanesh R: Surgical treatment of hepatocellular carcinoma. HPB (Oxford) 7: 42‑49, 2005.

10. Masaki T: MicroRNA and hepatocellular carcinoma. Hepatol

Res 39: 751‑752, 2009.

11. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ,

MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and

Rajewsky N: Combinatorial microRNA target predictions. Nat

Genet 37: 495‑500, 2005.

1733

12. Meng F, Henson R, Wehbe‑Janek H, Ghoshal K, Jacob ST

and Patel T: MicroRNA‑21 regulates expression of the PTEN

tumor suppressor gene in human hepatocellular cancer.

Gastroenterology 133: 647‑658, 2007.

13. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S,

Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, et al:

Cyclin G1 is a target of miR‑122a, a microRNA frequently

down‑regulated in human hepatocellular carcinoma. Cancer

Res 67: 6092‑6099, 2007.

14. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF and

Wong N: MicroRNA‑223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.

Gastroenterology 135: 257‑269, 2008.

15. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P,

Dienes HP and Odenthal M: MicroRNA gene expression profile

of hepatitis C virus‑associated hepatocellular carcinoma.

Hepatology 47: 1223‑1232, 2008.

16. Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M,

Augel lo C, R i massa L, P ressia n i T, Spagnuolo G,

Di Tommaso L, et al: MicroRNA‑425‑3p predicts response to

sorafenib therapy in patients with hepatocellular carcinoma.

Liver Int 35: 1077‑1086, 2015.

17. Gyöngyösi B, Végh É, Járay B, Székely E, Fassan M, Bodoky G,

Schaff Z and Kiss A: Pretreatment MicroRNA level and outcome

in Sorafenib‑treated hepatocellular carcinoma. J Histochem

Cytochem 62: 547‑555, 2014.

18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real‑time quantitative PCR and the 2(‑Delta Delta

C(T)) method. Methods 25: 402‑408, 2001.

19. El‑Serag HB: Hepatocellular carcinoma. N Engl J Med 365:

1118‑1127, 2011.

20. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S,

Sridhara R, Justice R and Pazdur R: Sorafenib for the treatment

of unresectable hepatocellular carcinoma. Oncologist 14: 95‑100,

2009.

21. Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T and

Kudo M: MicroRNAs for the prediction of early response to

sorafenib treatment in human hepatocellular carcinoma. Liver

Cancer 6: 113‑125, 2017.

22. Yoon EL, Yeon JE, Ko E, Lee HJ, Je JH, Yoo YJ, Kang SH,

Suh SJ, Kim JH, Seo YS, et al: An explorative analysis for

the role of serum miR‑10b‑3p levels in predicting response to

sorafenib in patients with advanced hepatocellular carcinoma.

J Korean Med Sci 32: 212‑220, 2017.

23. Díez‑Planelles C, Sánchez‑Lozano P, Crespo MC, Gil‑Zamorano J,

Ribacoba R, González N, Suárez E, Martínez‑Descals A,

Martínez‑Camblor P, Álvarez V, et al: Circulating microRNAs in

Huntington's disease: Emerging mediators in metabolic impairment. Pharmacol Res 108: 102‑110, 2016.

24. Miquelestorena‑Standley E, Tallet A, Collin C, Piver E,

De Muret A, Salamé E, Bourlier P, Kervarrec T, Guyétant S and

Pagès JC: Interest of variations in microRNA‑152 and ‑122 in a

series of hepatocellular carcinomas related to hepatitis C virus

infection. Hepatol Res 48: 566‑573, 2018.

25. Coenen‑Stass AM, Betts CA, Lee YF, Mäger I, Turunen MP,

El Andaloussi S, Morgan JE, Wood MJ and Roberts TC: Selective

release of muscle‑specific, extracellular microRNAs during

myogenic differentiation. Hum Mol Genet 25: 3960‑3974, 2016.

26. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, Poon RT,

Gao C and Luk JM: Circulating miR‑15b and miR‑130b in serum

as potential markers for detecting hepatocellular carcinoma: A

retrospective cohort study. BMJ Open 2: e000825, 2012.

27. Nakao K, Miyaaki H and Ichikawa T: Antitumor function of microRNA‑122 against hepatocellular carcinoma.

J Gastroenterol 49: 589‑593, 2014.

This work is licensed under a Creative Commons

Attribution-NonCommercial-NoDerivatives 4.0

International (CC BY-NC-ND 4.0) License.

...